IBM Does an About-Face on Facial Recognition Technology: Business Casual

Powered by RedCircle

On this Business Casual snippet, Tyler Kern, Taylor Bagley and Daniel Litwin discuss an announcement made my IBM on June 8th regarding the tech giant’s intention to stop offering facial recognition software for “mass surveillance or racial profiling”.

In 2019, a study conducted by the Massachusetts Institute of Technology found that none of the facial recognition tools from Microsoft, Amazon and IBM were 100% accurate when it came to recognizing men and women with dark skin. Further, a study from the US National Institute of Standards and Technology suggested facial recognition algorithms were far less accurate at identifying African-American and Asian faces compared with Caucasian ones. In a world currently riding the shockwaves of social unrest and protests calling for police reform in the wake of George Floyd’s death while being apprehended by officers in Minneapolis, this technological bias in gear provided to policing organizations has definitely been put under the microscope.

In support of IBMs move to abandon ‘biased’ facial recognition tech, Chief Executive Arvind Krishna, stated, “We believe now is the time to begin a national dialogue on whether and how facial recognition technology should be employed by domestic law enforcement agencies”.

As the first major company to back out of a technology largely used by law enforcement, the Business Casual dynamic duo break down Krishna’s letter to congress urging action against police malfeasance as well as more regulation on how law enforcement uses facial recognition technology, two different studies of Amazon’s facial recognition system by the ACLU which resulted in both Congress members and professional athletes being falsely matched with images of those in a mugshot database, whether IBM’s decision was based solely on current racially-charged events or just part of an ongoing massive restructuring within the company, and much more.

Bringing thought leadership to your day, MarketScale’s Business Casual keeps you current with technology leaps both forward and backward, the hottest topics and the newest trends shaping business and our world today. And for the latest thought leadership, news and event coverage across B2B, be sure to check out our industry pages.

Follow us on social media for the latest updates in B2B!
Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More